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Abstract
Introduction: The prevalence of diabetes is increasing rapidly, and individuals with diabetes are at
high risk for cardiovascular disorders. Subsequently the percentage of patients with diabetes
subjected to revascularisation, i.e. either percutaneous coronary intervention (PCI) or coronary
artery bypass grafting (CABG) also rises rapidly. The outcome of patients with diabetes after PCI
is worse than for patients without diabetes. Restenosis is the main limiting factor of the long-term
success of PCI. Although stents and antithrombotics improved outcome after PCI in both diabetics
and non-diabetics, diabetics still have a worse prognosis. This leads to the suggestion that the
restenosis mechanism in diabetics might be different from that in non-diabetics.
Conclusion: Several glucose lowering agents have been shown to influence the restenosis process
and thus the outcome after PCI. Current data of especially metformin and thiazolidinediones
indicate beneficial results as compared to insulin and sulfonylurea on restenosis. However, no large
trials have been undertaken in which the effect of glucose lowering agents on restenosis is
associated with improved outcome.
The purpose of this review is to summarize the effect of diabetes and glucose lowering agents on 
restenosis.
Introduction
In patients with diabetes, coronary artery disease (CAD) is
often present [1]. In comparison with patients without
diabetes, CAD is manifest earlier in life [1]. Especially
women with diabetes have a significantly higher risk of
developing CAD in comparison with men [2]. The calibre
of "normal" coronary arteries at coronary angiography is
smaller in patients with diabetes [3]. Diabetics have more
multi vessel coronary artery disease and form less often
collaterals [4,5]. Not only have patients with diabetes
more plaques, the plaques are more inflamed and
necrotic, forming a risk factor for rupture and therefore
myocardial infarction (MI) [6]. After MI diabetics have a
worse prognosis [7,8]. Patients with type 2 diabetes with-
out known CAD have a risk of a MI comparable to non-
diabetics with a previous history of MI [1]. It is therefore
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reasonable that CAD is accountable for 70–80% of the
diabetes related mortality [7]. Despite improvement of
coronary interventions, outcome in patients with diabetes
is impaired [1,8]. Restenosis is the main limiting factor of
the long-term success of percutaneous coronary interven-
tions (PCI) [9]. Possibly the restenosis mechanism in dia-
betics might be different from that in non-diabetics. The
purpose of this review is to summarize the influence of
diabetes on coronary restenosis and to summarize the
effect of glucose lowering agents on restenosis and out-
come.
Mechanism of Disease
Restenosis in diabetics
Diabetes is one of the most important risk factors for res-
tenosis after stent implantation, with odds ratios of 1.9 to
2.5 [10]. Diabetes leads to more extensive neointimal
hyperplasia, plaque formation, altered hemodynamics
and inadequate compensatory remodeling (table 1) [8].
Restenotic intimal hyperplasia in diabetics differs from
non-diabetics [7,11,12]. Diabetic vascular smooth muscle
cells exhibit increased rates of proliferation, leading to
luminal narrowing [11]. Furthermore, restenotic intimal
hyperplasia in diabetics has increased macrophage infil-
tration [11,12], lipid-rich and collagen-rich sclerotic con-
tent [8]. Diabetics have more vaso vasorum
neovascularisation, leading to intraplaque haemorrhage
[12]. Atherosclerotic laesions in diabetics are more prone
to rupture [11]. Furthermore, progression of atheroscle-
rotic plaques is accelerated in diabetics [8]. More extensive
neointimal hyperplasia and more rapid plaque formation
in diabetics leads to more restenosis and less stable
atherosclerotic plaques.
Several factors can account for the more extensive CAD in
patients with diabetes. First, diabetic patients are more
likely to have (co-) morbidities, among which are cardio-
vascular risk factors such as the metabolic syndrome.
According to the National Cholesterol Education Program
(NCEP) Expert Panel ATP-III-criteria (2001) the meta-
bolic syndrome consist of 3 or more of 5 risk factors:
hyperglycaemia, hypertension, decreased levels of HDL,
elevated levels of triglycerides and abdominal (visceral)
obesity [13]. The metabolic syndrome is associated with a
proinflammatory and prothrombotic state [7].
Several molecular mechanisms have been implicated in
hyperglycaemic-induced endothelial damage: activation
of protein-kinase C isoforms, increased hexosamine path-
way flux, increased advanced glycation end product for-
mation, increased polyol pathway flux and activation of
the proinflammatory nuclear transcription factor kappa-B
[7]. All these mechanisms are associated with overproduc-
tion of reactive oxygen species, which lead to endothelial
dysfunction, decreased vasodilatation and promotion of
atherosclerotic plaque formation [7]. Plaque formation is
one of the forces behind restenosis.
Peroxisome proliferator activated receptors (PPARs) play
an important role in the atherosclerotic process. Espe-
cially PPAR-gamma – a subfamily – is potent in reducing
plaque inflammation, in inhibiting expression of adhe-
sion molecules and in inhibiting formation of cytokines
Table 1: Key processes in restenosis in diabetics; the processes are specified to the elevated (↑) or decreased (↓) factors contributing 
to the elevated risk of restenosis in diabeticscompared to non-diabetics.
Influence of 4 Key Factors on Restenosis in Diabetics
Process Factor
Proinflammatory state ↑ C-peptide
↑ Resistin
↑ CRP
↑ Il-12
Prothrombotic state ↑ P2Y-receptor
↑ Endothelial damage by O2-radicals
Accelerated and unstable plaque formation ↑ Vascular smooth muscle cell proliferation
↑ Macrophage infiltration
↑ Lipid-rich
↑ Collagen-rich
↑ Vaso vasorum neovascularization
Haemodynamics ↓ Vessel lumen diameter
↑ Multivessel disease
↑ ViscosityCardiovascular Diabetology 2009, 8:41 http://www.cardiab.com/content/8/1/41
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(e.g. interleukin 12 [IL-12]) [7]. It is known IL-12 is an
important factor in the pathophysiology of atherosclero-
sis and leads to up-regulation of T1-helper response,
which is associated with CAD [14]. Wegner et al (2008)
demonstrated that IL-12 levels are elevated in type 2 dia-
betics based on fasting proinsulin due to insulin resist-
ance [14].
Furthermore, insulin resistance leads to upregulation of
the P2Y-receptor-pathway, a platelet membrane protein
[15].
In patients with diabetes increased levels of C-peptide, a
cleavage product of proinsulin, circulate. C-peptide pro-
motes monocyte and T-lymphocyte recruitment into the
vessel wall [16]. Walcher et al (2006) showed that in early
arteriosclerotic lesions of diabetic subjects, C-peptide
colocalized adherent to vascular smooth muscle cells
(VSMCs) in the media [16]. C-peptide induced phospho-
rylation of Src-kinase, as well as activation of the extracel-
lular signal-regulated kinase 1/2 (ERK 1/2) and
phosphatidylinositol 3-kinase (PI3K) leading to increased
cell proliferation.
Another pathway involved in proliferation of VSMCs is
through the effects induced by resistin, an adipokine,
which is elevated in diabetes [17]. One study has shown
that resistin has a proinflammatory effect on endothelial
cells [17]. Calabro et al (2004) showed that VSMC prolif-
eration was induced by resistin [17]. Resistin induces
VSMC proliferation through both ERK 1/2 and Akt signal-
ing pathways. Furthermore, On et al (2007) demonstrated
that elevated preprocedural serum resistin levels may
prove to be a useful biological marker for coronary artery
disease and restenosis in patients with type 2 diabetes
[18].
Coronary Interventions and Restenosis
Coronary stents
The long-term benefit of balloon angioplasty is mainly
limited by restenosis of the treated segment, occurring in
one third to half of all treated patients [19]. Restenosis
causes recurrent myocardial ischemia and therefore neces-
sitates additional revascularisation [19]. Initially, bare
metal stents (BMS) were introduced to overcome flow
limiting dissections following balloon angioplasty. In
addition it was shown that stents resulted in a lower rate
of restenosis and recurrent ischemia. Stents prevent vessel
recoil and negative remodeling – important steps in lumi-
nal narrowing – and thereby reduce the possibility of res-
tenosis [20]. Intimal hyperplasia, another important step
in luminal narrowing, is not prevented by stenting and is
the main reason for in-stent restenosis.
Drug-eluting stents (DES) are covered with polymers of
immunosuppressive agents e.g. paclitaxel, sirolimus, and
zotarolimus, which are progressively eluted the first weeks
after implantation. DES treatment in both diabetics and
non-diabetics leads to a reduction of target vessel revascu-
larization (TVR) and restenosis after PCI in comparison to
BMS [10]. A recent meta-analysis by Stettler et al (2009)
demonstrated that in 3852 diabetics and 10947 non-dia-
betics DES and BMS have comparable hazard ratios for
mortality [21]. Furthermore, this study confirmed that
DES lead to a decrease in revascularization rates compared
with BMS in people both with and without diabetes.
Jensen et al (2009) compared paclitaxel eluting stents and
sirolimus eluting stents in 74 diabetics and found that
paclitaxel eluting stents had increased lumen reduction
[22]. Fröbert et al (2009) compared four types of drug
eluting stents in 8,231 patients with diabetes, and found
significant differences in restenosis rates, favouring the
paclitaxel-eluting stents [23]. However, Lee et al (2009)
demonstrated in the Drug-Eluting-Stents in Diabetes
(DES-DIABETES) trial with 400 patients that on the long-
term the sirolimus-eluting stent lead to a reduction of res-
tenosis, TVR and major adverse cardiac events (MACE)
[24]. These results were confirmed by a meta-analysis of
16 randomized trials by Schömig et al (2007) [25].
Bare metal stent versus coronary artery bypass grafting
In non-diabetics there is no difference in mortality
between PCI with BMS and coronary artery bypass graft-
ing (CABG) for multivessel disease, whereas in diabetics
CABG is thought to have a favourable outcome in com-
parison with PCI [26]. The Bypass Angioplasty Revascular-
ization Investigation (BARI)-trial (2007) demonstrated
that in 1,476 non-diabetics there was no difference
between elective PCI and CABG, for both short-term and
long-term survival, with a 10-year mortality rate of 23.0%
in the PCI group and 22.7% in the CABG group. However,
among the subgroup of patients with treated diabetes (n =
353), CABG had a long-term benefit over PCI, based on
reduced cardiac mortality in the patients undergoing
CABG, with mortality rates of PCI versus CABG of 54.5%
versus 42.1%, respectively [26]. The recent meta-analysis
by Hlatky et al (2009) showed that in 10 trials with 7,812
patients confirmed the long-term benefit of CABG [27]. In
the 1,233 patients with diabetes the 5-year mortality rate
was significantly lower with 12.3% in the CABG group
versus 20.0% in the PCI group. In the recent Bypass Angi-
oplasty Revascularization Investigation 2 Diabetes (BARI
2D) (2009) with 2368 type 2 diabetes patients the abso-
lute rates of major adverse cardiac events were equal in
patients treated with PCI (n = 798) or CABG (n = 378), i.e.
23% versus 22.4% [28]. In the BARI 2D both BMS and
DES were used.
Drug eluting stents versus coronary artery bypass grafting
Conversely, when comparing DES with CABG for multi-
vessel disease, the Synergy between PCI with Taxus andCardiovascular Diabetology 2009, 8:41 http://www.cardiab.com/content/8/1/41
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Cardiac Surgery (SYNTAX) trial by Serruys et al (2009)
with 1800 patients showed that the rates of myocardial
infarction and mortality were similar between PCI and
CABG groups [29]. Major adverse cardiac and cerebrovas-
cular events (MACCE) were significantly increased in the
PCI group, mainly due to higher rates of revascularization.
In the SYNTAX patients with more severe coronary artery
disease, and especially those with diabetes, CABG was
related to a higher freedom from re-intervention. These
results were corroborated by Tarantini et al (2009), Dae-
men et al (2008), Briguori et al (2007) and Lee et al
(2007), respectively including 220, 159, 218 and 205 dia-
betics [30-33].
Antiplatelet Agents
Thienopyridines
Insulin resistance leads to upregulation of the P2Y-recep-
tor-pathway, a platelet membrane protein [15]. The P2Y-
receptor is the target of the active metabolite of clopidog-
rel. Post-PCI this results in increased platelet reactivity in
diabetics [15]. Therefore, a higher dose of thienopyridines
seems needed in diabetics to attain an adequate anti-
thrombotic regiment [34]. Illustrating the importance of
antithrombotic therapy in diabetics, Stettler et al (2009)
demonstrated that, in contrast to non-diabetics, drug elut-
ing stents in diabetics are only safe to use if adequate
antiplatelet therapy is administered [21]. Wiviott et al
(2008) demonstrated in 3,146 patients with diabetes that
prasugrel compared with clopidogrel leads to a reduction
in cardiovascular death, MI and stroke (12.2% versus
17%) [35]. This illustrates the potential to overcome the
relative antiplatelet drug resistance of diabetes with novel
pharmacologic agents.
Glycoprotein IIb/IIIa receptor blockade
During PCI both profound vessel wall injury and plaque
rupture occur. This triggers activation of the coagulation
cascade, and adhesion, activation and aggregation of
platelets. Platelets express more glycoprotein (GP) IIb/IIIa
receptors in diabetics and have a tendency to aggregate,
especially in the presence of hyperglycemia [1,36]. Type 2
diabetics on insulin have greater platelet aggregation than
type 2 diabetics non treated with insulin [36]. Labinaz et
al (2002) compared GP IIb/IIIa receptor blockers in PCIs
in diabetics (n = 466) and non-diabetics (n = 1,595) [37].
The group of patients receiving GP IIb/IIIa receptor block-
ers had significant decreased rates of mortality, TVR and
MI. However, the relative risk reduction for diabetics was
similar to the reduction in non-diabetics.
Glucose Lowering Agents and Restenosis
The effect of treatment with glucose lowering agents on
macrovascular disease is not well established. In the Euro-
pean Heart Survey a pronounced decrease in cardiovascu-
lar events in patients with newly detected diabetes
prescribed glucose lowering agents compared with those
not receiving such treatment was observed [38]. Several
retrospective analyses of databases showed differences in
coronary revascularization and MI in patients treated with
different regimens (table 2). The major recognized limita-
tion of these analyses is the bias of patients with a higher
risk profile treated with insulin or combination therapy
[39]. The above-mentioned BARI 2D also showed that
after a follow-up period of more than 3 years in patients
treated with PCI that no survival benefit could be
observed between patients treated with metformin or
TZDs (insulin sensitization, 10.2%) as compared to insu-
lin or sulfonylurea (insulin provision, 11.4%) [28]. How-
ever, the rate of major cardiovascular events was 3.8%
lower in the insulin sensitization group treated with PCI,
albeit non-significant. The effect of the individual glucose
lowering agents was not reported (yet). The effect of glu-
cose lowering, i.e. more strict versus moderate glucose
control, on outcome has been extensively investigated. In
a meta-analysis (2009) of 5 large trials the rate of non-
fatal myocardial infarction was significantly lower in the
stricter compared to the moderate glucose control group,
10.0% versus 12.3% [40]. Whether strict glucose control,
irrespective of specific glucose lowering agents, is related
to a reduction of restenosis is not known.
Thiazolidinediones
Thiazolidinediones (TZDs) are peroxisome proliferator
activated receptors (PPAR)-gamma agonists. They
decrease insulin resistance, levels of CRP, fibrinogen,
LDL-cholesterol, triglycerides and resistin in comparison
with placebo [17,41]. TZDs inhibit VSMC proliferation,
ameliorating intimal hyperplasia and restenosis [42].
Under high glucose conditions the inhibitory activity of
VSMC proliferation by pioglitazone and rosiglitazone is
enhanced, in contract to troglitazone [42].
Several studies have suggested the preventive effects of
TZDs on atherosclerosis, restenosis, in-stent restenosis,
and reocclusion after PCI in patients with type 2 diabetes.
Table 2: Elevated (↑) or decreased (↓) risk of restenosis, target 
laesion vascularization (TLR), death or myocardial infarction 
(MI) of the different groups of glucose lowering agents after PCI.
Risk Modulation of Glucose Lowering Agents in Diabetics After PCI
Agent Restenosis TLR Death MI
TZDs ↓↓ ↓ -
Sulfonylurea ↑ - ↑ -
Biguanides - ↓ - ↓
Insulin ↑↑ ↑ ↑Cardiovascular Diabetology 2009, 8:41 http://www.cardiab.com/content/8/1/41
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Takagi et al (2002) showed in a randomized study that in
55 patients with 60 lesions troglitazone was associated
with reduced angiographic in-stent restenosis and
neointimal tissue proliferation [43]. Choi et al (2004)
found in a case-control study with 83 patients treated with
rosiglitazone that at 6 months a significant reduction in
restenosis rate, greater minimal lumen stent diameter and
albeit non-significant lower TVR [44]. Nishio et al (2006)
observed in randomized study with 54 patients that treat-
ment with pioglitazone attenuated neointimal thickening
regardless of the type of PCI and resulted in less late lumi-
nal loss [45]. The meta-analysis of Rosmarakis et al in
2007 already showed that TZDs decrease the need for tar-
get vessel revascularization when 5 trials with 235 patients
were analyzed [46]. The meta-analysis by Geng et al pub-
lished in 2009 consisted of 8 trials with 366 patients and
showed that TZDs were associated with a significant
reduction in the risk of in-stent restenosis in both diabetic
and non-diabetic patients [47]. They also observed a
reduction in late lumen loss, percent diameter stenosis,
neointimal area/volume, and target lesion revasculariza-
tion. Recently, Finn et al (2009) randomly assigned 65
diabetics to rosiglitazone or placebo and could not con-
firm the above described results on luminal loss [48]. An
interesting observation was made by Nishio et al (2006),
i.e. that in 38 type 2 diabetics similar restenosis rates were
present in patients treated with either a BMS with piogli-
tazone or sirolimus-eluting stent without pioglitazone
[49]. Fang et al (2007) demonstrated that rosiglitazone
therapy in comparison to standard antidiabetic therapy
without rosiglitazone in type 2 diabetics leads to a signif-
icant decrease in restenosis and mortality [50]. However,
the intervention group significantly used more insulin
and biguanides, which might lead to bias of the observed
effects. In a study with 417 patients referred for stress test-
ing to evaluate chest pain by Kapinya et al (2008), 222
were treated with conventional therapy only (insulin and
insulin secretagogues) and 195 as being treated with insu-
lin sensitizers (metformin and thiazolidinediones) [51].
The rate of ischemia and MI was not significantly lower in
patients treated with thiazolidinediones. In the Pioglita-
zone Effect on Regression of Intravascular Sonographic
Coronary Obstruction Prospective Evaluation (PERI-
SCOPE)-trial, Nissen et al (2008) demonstrated that in
patients with type 2 diabetes and coronary artery disease
treatment with pioglitazone compared with glimepiride
results in a significantly lower rate of progression of coro-
nary atherosclerosis, as measured with intravascular ultra-
sound [52]. The patients receiving pioglitazone also had
significantly reduced levels of CRP, triglycerides and
HbA1c and an increase in HDL. Nonetheless, this trial did
not show any significant differences in clinical outcome
between pioglitazone and glimepiride. Recently, Clem-
enti et al (2009) demonstrated in 25 patients with diabe-
tes that administration of pioglitazone combined with
atorvastatin leads to a significant regression of coronary
atherosclerosis [53].
Biguanides
The precise mechanism of action of biguanides, i.e. met-
formin, is not completely elucidated. Metformin has insu-
lin sensitizing effects, and may therefore have
cardiovascular effects [54]. In the previously described
study by Kapinya et al (2004), only the 125 patients on
metformin had lower rates of ischemia and MI [51]. In
diabetics undergoing PCI, Kao et al (2004) showed that
metformin-therapy in comparison with insulin and sulfo-
nylurea was associated with a reduced risk of MI and mor-
tality [54]. It is not clear whether the superiority of
metformin therapy in this trial is due to beneficial effects
of the metformin or is due to possible adverse effects of
the sulfonylurea on atherosclerosis. In the study by
Walker et al (2008) it was observed that patients treated
with metformin were less likely to need revascularization
or suffer from MI compared to other treatment regimens
[39]. Comparable results were observed by Casscells et al
with 232,000 diabetics (2008) [55]. On the other hand in
a post-hoc analysis of the Diabetes and Insulin-Glucose
Infusion in Acute Myocardial Infarction (DIGAMI)-2 trial
with 1181 patients no differences on cardiovascular mor-
tality were observed, although metformin was associated
with a significant lower rate of non-fatal MI and stroke as
compared to sulfonylurea or insulin treatment [56].
Adversely, metformin therapy may also lead to progres-
sion of coronary artery disease. Chronic use of metformin
leads to decreased intestinal absorption of group B vita-
mins and folate. These deficiencies lead to elevated levels
of homocysteine, which accelerates progression of cardio-
vascular disease due to adverse effects on platelets,
endothelium and clothing factors [57].
Sulfonylurea
Sulfonylurea act through binding to the sulfonylurea
receptor on the surface of pancreatic β cells. This results in
closure of the potassium channels and thereby depolari-
zation of the cell membrane and, in turn, opening of volt-
age-dependent calcium channels. The influx of calcium
causes microtubules to contract and the exocytosis of
insulin from vesicles. Garratt et al (1999) report that sul-
fonylurea drugs are associated with an increased risk of in-
hospital mortality among 185 diabetic patients undergo-
ing angioplasty for acute myocardial infarction [58]. No
association between sulfonylurea drugs and late adverse
events after primary PCI has been observed. The explana-
tion for this early risk is not an increase in ventricular
arrhythmias, but reflects the deleterious effects of sulfony-
lurea drugs on myocardial tolerance for ischemia and
reperfusion. Blockade of K-ATP-channels, which is the tar-
get of sulfonylurea drugs, promotes insulin release in pan-Cardiovascular Diabetology 2009, 8:41 http://www.cardiab.com/content/8/1/41
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creatic B-cells, but also affects in certain sulfonylurea
drugs cardiac tissue and coronary arteries [59]. This leads
to greater vulnerability of the myocardium to ischemia,
which results in the increased clinical manifestations of
ischemia [57,60].
Sulfonylurea drug use lead to elevated IL-12 serum levels
in type-2 diabetics, induced by peripheral insulin resist-
ance and beta cell dysfunction, as expressed by fasting
serum proinsulin levels. Therefore, according to the
hypothesis by Wegner et al, sulfonylurea drugs can pro-
mote atherosclerosis [14].
Insulin
Huang et al demonstrated that high levels of insulin are
potent in stimulating VSMC proliferation [61]. The clini-
cal relevance of this observation has yet to be investigated.
In all the above-described studies patients treated with
insulin had higher rates of either ischemia or infarction.
Conclusion
Diabetes is a major risk factor for adverse events after PCI.
Diabetics have higher rates of mortality, myocardial inf-
arction and target vessel revascularisation than non-dia-
betics. Recent therapeutical antithrombotic and
percutaneous developments improved the prognosis both
for diabetics and non-diabetics, thereby maintaining a
worse prognosis for diabetics.
The exact mechanism of restenosis is not yet completely
understood, although several contributing factors have
been identified. Several glucose lowering drugs influence
the restenosis process. Current data of especially met-
formin and thiazolidinediones indicate beneficial results
as compared with insulin and sulfonylurea. However, no
large prospective trials in which the clinical impact of
these drugs on restenosis is investigated have been under-
taken.
The prognosis of diabetics undergoing PCI remains worse
than non-diabetics. Possibly the best way to improve the
prognosis of diabetics undergoing PCI is to prevent diabe-
tes or to pursue adequate diabetes regulation.
Future area of interest
Due to the negative influence of diabetes on prognosis
after PCI, glucose lowering therapy might have a substan-
tial influence on coronary restenosis and the worse prog-
nosis of diabetics. Future studies might determine
whether or not the type of glucose lowering agent has
influence on restenosis after PCI.
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